Dr. Reddy’s (RDY) Laboratories, a wholly-owned subsidiary of Dr. Reddy’s Laboratories, announced that it has entered into a license agreement with Shanghai Henlius Biotech related to the development and commercialization of HLX15, Henlius’s investigational daratumumab biosimilar candidate to Darzalex & Darzalex Faspro. Under the terms of the agreement, Henlius will be responsible for development, manufacturing and commercial supply, and may receive up to a total of $131.6M, including an upfront payment of $33M and milestone payments. In addition, Henlius is eligible to receive royalties on annual net sales of the product. Dr. Reddy’s gets exclusive rights to commercialize the subcutaneous as well as intravenous formulations of HLX15 in the United States and Europe.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDY:
- Dr. Reddy’s Laboratories Schedules Investor Conference Participation
- Dr. Reddy’s Laboratories to Engage with Investors in Mumbai Conference
- Dr. Reddy’s Laboratories Engages with Investors in Upcoming Conferences
- Dr. Reddy’s Faces Tax Penalty with No Material Impact
- Dr. Reddy’s Faces GST Penalty, Evaluates Appeal